Germany’s Merck forecasts little or no improvement in earnings this year, with stiff competition for its blockbuster multiple-sclerosis treatment and higher research spending likely to offset the impact of recent acquisitions.
WSJ.com: US Business, Wall Street Journal: Business
Tue, 03/03/2015 - 3:43am
Germany’s Merck forecasts little or no improvement in earnings this year, with stiff competition for its blockbuster multiple-sclerosis treatment and higher research spending likely to offset the impact of recent acquisitions.